Is Nippon Shinyaku's 8x Multiple Already the Price of the Uptravi Cliff?

Nippon Shinyaku’s year to March 2026 produced revenue of ¥170.77bn and a net profit margin of 17.4%. At the estimated share price of 3,432 yen, the trial market capitalization is about ¥231.3bn, or roughly 7.8 times that year’s net income of ¥29.72bn. It looks cheap. Twenty-nine percent of sales, though, is industrial-property income linked to overseas sales of Uptravi, an oral drug for pulmonary hypertension. The company’s own target for operating profit in fiscal 2028, the last year of its seventh medium-term plan, is ¥30bn, below the latest ¥35.496bn. Is this multiple the market’s price for generics arriving in April 2027, or a margin of safety? That is the only question this note tries to answer.

The year labels do not overlap. The column 2026 in the tables is the year ended March 2026. Company guidance covers the year ending March 2027, which is still before the cliff. Generics enter from April 2027, which is fiscal 2027, the year ending March 2028. The ¥30bn operating-profit target sits in the plan’s final year, fiscal 2028, the year ending March 2029.

The profit pool is an Uptravi royalty, not the pharmacy counter

Nippon Shinyaku is a Kyoto drug and functional-food company. It has six consolidated subsidiaries. In the United States, NS Pharma, Inc. handles sales, in- and out-licensing, and clinical development. Of ¥170.771bn in revenue for the year ended March 2026, pharmaceuticals were ¥148.484bn (86.9%) and functional food was ¥22.287bn (13.1%).

Pharmaceuticals are not one product line. The earnings release splits them into product sales of ¥90.062bn, industrial-property income of ¥49.457bn, and co-promotion income of ¥8.964bn. Industrial-property income rose 8.5%, and the company attributes that to royalties on overseas Uptravi sales. ¥49.457bn is 29.0% of ¥170.771bn. The margin is not only what the company sells at the counter. It is a rate applied to a partner’s sales.

At the fiscal 2026 first-quarter briefing, the president said generics arrive from April 2027, that a crystal-form patent will not keep them out, and that the royalty rate does not change after entry. The royalty falls only because the partner’s sales fall. The partner is Johnson & Johnson. This is not deferred revenue. The company recognizes the royalty as the partner’s sales occur.

Candidates for a wide moat are the in-house nucleic-acid franchise, centered on Duchenne muscular dystrophy, in-licensed rare-disease drugs, the prescribing base of Uptravi, Fintepla, and Erleada, and quality control in functional food. Research and development was ¥36.713bn, 21.5% of sales. A profit pool that is 29% one royalty, with an end date you can put on a calendar, is not itself a wide moat. The moat argument starts only if the next products fill the hole the royalty leaves.

Functional food is a separate leg. Protein preparations were ¥13.680bn, quality-stabilizing preservatives ¥3.269bn, supplements ¥2.821bn (up 16.8%), and health-food ingredients ¥1.214bn. At 13% of sales, that leg does not replace the pharmaceutical cliff on its own.

Revenue kept rising. The net-income dip is the tax rate

The columns 2024, 2025, and 2026 are the years ended March 2024, March 2025, and March 2026. Revenue rose from ¥148.26bn to ¥170.77bn, a fourth consecutive increase. Net income fell from ¥32.56bn to ¥29.72bn, and the net profit margin went from 20.3% back to 17.4%, the same rate as the year ended March 2024.

The drop is not a disappearance of the business. In the consolidated income statement, profit before tax rose from ¥36.135bn to ¥36.462bn (+0.9%), and operating profit rose from ¥35.450bn to ¥35.496bn (+0.1%). Income tax expense rose from ¥3.574bn to ¥6.734bn, so the tax charge went from about 9.9% of pretax profit to about 18.5%. Net income attributable to owners fell from ¥32.558bn to ¥29.721bn, down 8.7%. The chart rounds that last figure to ¥29.72bn.

Costs moved the other way. Cost of sales was ¥57.460bn, a 33.6% ratio and 1.7 points worse than the prior year. Selling, general, and administrative expenses were ¥43.565bn, up 14.6%. Research and development was ¥36.713bn, up 6.9%. The company points to NS Pharma’s selling costs and Uptravi promotion fees. Other income, including foreign-exchange gains, rose from ¥0.874bn to ¥3.025bn, and other expenses fell from ¥2.186bn to ¥0.560bn. Higher sales and that non-operating income roughly offset the cost increase.

On the main-product table in the earnings supplement, domestic Uptravi was ¥17.593bn (up 17.5%), Fintepla was ¥3.980bn (up 92.5%), and Erleada, booked as the company’s own product sales from October 2025, was ¥5.961bn. Viltepso was ¥21.188bn (down 2.7%), of which the United States was ¥16.413bn (down 4.1%). The company says U.S. patients are younger, so the dose per patient fell. Products that are still growing sit next to one that has already stalled.

Guidance for the year ending March 2027 is revenue of ¥200bn (up 17.1%), operating profit of ¥38bn (up 7.1%), and net income of ¥30.3bn (up 1.9%). The same supplement puts industrial-property income at ¥53bn, Erleada at ¥14.4bn, Fintepla at ¥6.1bn, and U.S. Deramiocel sales at ¥11.4bn. Those are company forecasts, not actuals, and they are not in the table. The company plans to keep growing through the year before the cliff. The March 2026 results do not yet contradict that sequence.

¥32.6bn of owner earnings is the year intangible spending stopped

(* Simulation assumptions: estimated share price 3,432 yen, required return 5%)

Owner earnings are net income plus depreciation and amortization, minus cash spent on property, plant, and equipment and on intangible assets. For the year ended March 2026 that is ¥29.721bn + ¥6.629bn − ¥2.981bn − ¥0.801bn = ¥32.568bn, which matches the table. Divided by the 5% required return, owner-earnings value is ¥651.36bn.

The ¥3.78bn in the prior year is not a vanished business. The same formula includes ¥31.441bn of cash spent on intangible assets, which pulled owner earnings down to ¥3.780bn. In the latest year that cash outlay was ¥0.801bn. The earnings supplement shows capital expenditure excluding upfront and milestone payments of ¥5.055bn and ¥5.140bn in the two years, so the prior year’s large outflow sits on the upfront-and-milestone side. Which contract that payment belonged to is not identified in the materials used here. The recorded fact is narrower: one year of intangible cash spending compressed owner earnings, and when that spending stopped they rebounded to ¥32.568bn. This is not maintenance capital expenditure. It swings with in-licensing checks, and it can swing again.

The estimated price of 3,432 yen times 67,400,984 shares after treasury stock is a trial market capitalization of ¥231.320bn. Owner-earnings value of ¥651.36bn is about 2.8 times that. Turn the comparison around: 5% of the trial market cap is about ¥11.6bn of owner earnings a year, just over a third of the latest ¥32.568bn. On trailing numbers the margin of safety looks wide. It is wide only if intangible spending stays near ¥0.801bn and owner earnings stay near ¥32.6bn.

The web market capitalization on 23 October 2026 was ¥241.103bn, which is the full share count of 70,251,484, including treasury stock, times 3,432 yen. The gap versus the trial figure is about 4%, inside a 30% check. The 2026 high was 5,787 yen on 8 January and the low was 3,322 yen on 8 October. The 3,432 yen used here matches the close after that decline. The market is not still pricing this company at the high. If the de-rating is the cliff, the 2.8 times trailing owner-earnings value is not a margin of safety. It is a price for lower future earnings.

Most of the ¥124bn in net cash is not cash

Net cash here is (current assets − inventories) + (investment securities × 70%) − liabilities. At March 2026, current assets were ¥183.086bn, inventories ¥51.595bn, non-current other financial assets ¥67.356bn, and liabilities ¥54.488bn. That is (183.086 − 51.595) + (67.356 × 0.7) − 54.488 = ¥124.152bn, matching the table. The net current asset ratio of 53.671% is that ¥124.152bn divided by the trial market cap of about ¥231.3bn.

Cash and cash equivalents were ¥76.592bn. Subtract liabilities of ¥54.488bn and ¥22.104bn remains. The gap up to ¥124.152bn is receivables and other current assets, excluding inventories, plus a 30% haircut on investment securities. Non-current other financial assets rose from ¥39.492bn to ¥67.356bn. Equity attributable to owners rose from ¥247.028bn to ¥291.551bn, an increase of ¥44.523bn. Retained earnings rose by only ¥24.051bn, from ¥222.640bn to ¥246.691bn, so almost half of the equity increase is mark-to-market on financial assets rather than earnings retained. Book value per share in the filing is 4,325.63 yen. Against the estimated price of 3,432 yen, that is a price-to-book ratio of about 0.79. The denominator includes those unrealized gains.

Liabilities are mostly trade payables of ¥26.132bn and income taxes payable of ¥6.979bn. Other financial liabilities are ¥0.273bn current and ¥0.235bn non-current. Lease liabilities are ¥0.913bn current and ¥1.654bn non-current. This is not a balance sheet that borrows its profit. The equity ratio is 84.2%. The dividend is 124 yen, a 28.1% payout, and a 3.1% dividend on equity. The company guides the same 124 yen for the next year. The downside support is not ¥22.1bn of cash after liabilities. It is the calculation that, even after a 30% haircut on securities, net cash is still a bit more than half of the trial market cap. Whether those securities keep their marks is a separate assumption, not a recorded fact.

Generics from April 2027, and ¥11.4bn still inside the forecast

The main risk is the Uptravi patent cliff. The seventh medium-term plan says industrial-property income, most of it royalty, will fall sharply when the patent expires in fiscal 2027. The securities report treats the coming Uptravi cliff as the premise for the next stage of growth. Because ¥49.457bn was 29% of sales in the year ended March 2026, a thinner royalty changes what a 17.4% net margin and an 8x multiple mean. The rate can stay fixed and the royalty can still fall with the partner’s sales.

The quantitative targets for fiscal 2028 are revenue of ¥230bn, operating profit of ¥30bn, EPS of 341 yen, ROE of at least 8%, and ROIC of at least 9%. The year ended March 2026 produced operating profit of ¥35.496bn, basic EPS of 441.00 yen, and an ROE of about 11% if net income is divided by the average of opening and closing equity attributable to owners. The profit and return targets sit below the latest results. The plan also sets ¥190bn of research and development spending over the plan period, money aimed at getting past the cliff. How much of that lower profit the share price already discounts is an interpretation. Trailing owner-earnings value does not settle it.

The next item is the ¥11.4bn of U.S. Deramiocel (CAP-1002) sales inside guidance for the year ending March 2027. On 29 July 2026 an FDA advisory committee voted 3 to 9 against the cardiomyopathy efficacy claim. The PDUFA goal date moved from 22 August 2026 to 22 November 2026, which Nippon Shinyaku disclosed on 25 August 2026. On 7 May 2026 Capricor sued to terminate the U.S. distribution agreement, and the earnings release records that as a subsequent event. Neither approval nor the contract is settled as a basis for that ¥11.4bn. As of this review on 25 October 2026, the PDUFA outcome was not yet known.

U.S. Viltepso sales were already down, with the company citing competition in Duchenne and stricter insurance reviews. RGX-121 was placed on clinical hold in January 2026, the hold was later lifted, and the FDA issued a complete response letter in February 2026 that the company has disputed. Annual drug-price cuts, generics, the cost ratio moving to 33.6%, and a stronger yen reducing sales and operating profit are risks the company itself lists.

There is also room on the upside, next to the actuals. Erleada’s first year of own-product sales was ¥5.961bn, against guidance of ¥14.4bn. Fintepla guidance is ¥6.1bn. Functional-food supplements grew 16.8%. Each is a candidate to fill the royalty hole. None of them had filled it by March 2026, because the hole was not open yet.

Wait. The cheap multiple depends on the royalty surviving

Nippon Shinyaku has a prescribing base in rare disease and pulmonary hypertension, and the year ended March 2026 was still a growth year with a 17.4% net margin. The stance here is to wait. Two reasons. First, a multiple of about 7.8 times and owner-earnings value of ¥651.36bn look generous only if the ¥32.568bn earned in a year of ¥0.801bn intangible spending continues. Second, the company itself set fiscal 2028 operating profit at ¥30bn, below the latest ¥35.496bn, and 29% of sales is an Uptravi royalty that faces generics from April 2027. Net cash of ¥124.152bn is about 54% of the trial market cap, but cash minus liabilities is about ¥22.1bn, and much of the difference is investment securities taken at 70%. A price-to-book ratio of about 0.79 plus that net cash is not enough to call the downside covered. The prior year’s owner earnings of ¥3.78bn are also not evidence that the business broke.

Triggers that would turn the stance more bullish

• Industrial-property income for the year ending March 2027 holds near the company’s forecast of ¥53bn. The check is the main-product sales table in the earnings release.
• On that same table, Erleada is near the ¥14.4bn forecast and Fintepla is near the ¥6.1bn forecast. That is the test of whether the next products are growing on plan in the year before the cliff.

Triggers that would turn the stance toward a pass

• After April 2027, industrial-property income falls sharply from ¥49.457bn, and the outlook for fiscal 2028 operating profit drops below the plan target of ¥30bn. The check is the earnings release and progress against the medium-term plan.
• The Deramiocel PDUFA goal date of 22 November 2026, or the outcome of the Capricor suit, removes the ¥11.4bn of U.S. sales built into guidance for the year ending March 2027. The check is Nippon Shinyaku’s IR releases.

Owner-earnings value at 2.8 times the trial market cap is not a reason to buy. The question is whether earning power near ¥32.6bn is still there after the royalty shrinks, and the product table is where that shows up.

Want to simulate the "fair value" of Nippon Shinyaku Co., Ltd.?

Interested in digging deeper into the financial data for Nippon Shinyaku Co., Ltd. featured in this article?

At okuriru.com, you can run simulations for Nippon Shinyaku Co., Ltd. based on Buffett-style "owner earnings." Enter your required rate of return (hurdle rate) to instantly calculate a theoretical stock price.

👉 Calculate Nippon Shinyaku Co., Ltd.'s theoretical stock price

Resolve the question "Is this stock fairly priced?" using your own criteria. CSV downloads of financial data are available too!